Advertisement

Cyclosporine Formulations

  • Venkataraman Ramanathan
  • J. Harold Helderman

Abstract

Borel et al in 1972 discovered the immunosuppressive properties of cyclosporine (CyA) and since then this fungal metabolite extracted from Tolypocladium inflatum, has revolutionized the field of clinical transplantation. Approved in 1983 by Food and Drug Administration (FDA) for widespread clinical use, this drug has improved the graft survival and has been the cornerstone in most immunosuppression protocols. The more selective inhibition of T lymphocyte immunity by CyA was unique when it was discovered compared to its predecessor drugs like steroids and azathioprine. Since its use in clinical practice, marked improvements in outcome have been accomplished in one year and in chronic renal allograft survival and routinely successful heart, liver, pancreas, and lung transplants are possible. Cyclosporine is a cyclic polypeptide consisting of 11 aminoacids and molecular weight of approximately 1200 (C62 H111 N11 012) The cyclic structure is necessary for its immunosuppressive effect.

Keywords

Calcineurin Inhibitor Soft Gelatin Capsule Tolypocladium Inflatum Poor Absorber Cyclosporine Formulation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Kovarik JM, Mueller EA, Van Bree JB et al: Transplantation 58: 658, 1994.PubMedGoogle Scholar
  2. 2.
    Kahan BD, Dunn J, Fitts C et al: Transplantation 59: 505, 1995.PubMedGoogle Scholar
  3. 3.
    Helderman J.H.: Lessons from the Neoral Global Database. Transplant Proc 30(5): 1721–1722, 1998.PubMedCrossRefGoogle Scholar
  4. 4.
    Gudmundsdottir H and Turka LA: New therapies for transplant rejection. J Am Soc Nephrol 10: 1356–1365, 1999.PubMedGoogle Scholar
  5. 5.
    Jain J, McCaffrey PG, Valge-Archer VE & Rao A: Nuclear factor of activated T cells contains Fos and Jun. Nature 356: 801–804, 1992.PubMedCrossRefGoogle Scholar
  6. 6.
    Abrass CK, Berfield AK, Stehman-Breen C, Alpers CE and Davis CL: Unique changes in Interstitial extracellular matrix composition are associated with rejection and cyclosporine toxicity in human renal allograft biopsies. Am J Kidney Dis 33: 11–20, 1999.PubMedCrossRefGoogle Scholar
  7. 7.
    Hariharan S. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 342:605–612. 2000.PubMedCrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers 2001

Authors and Affiliations

  • Venkataraman Ramanathan
  • J. Harold Helderman

There are no affiliations available

Personalised recommendations